Back to results
US 2026/0232731 A1Published application
Function-enhanced cell therapy
AssigneeNanjing Bioheng Biotech Co., Ltd.
InventorsYali ZHOU, Yingxiu TANG, Jianqiang HOU, Dong ZHENG, Jiangtao REN
Life of this patent
Estimating the term…
Abstract
An engineered cell that expresses an exogenous immunosuppressive molecule and expression of at least one endogenous gene thereof selected from the group consisting of: Fas, TNFR1, DR3, DR4, DR5, TGFBR1 and TGFBR2 is down-regulated. The present disclosure further relates to the engineered cell and a composition comprising the cell.
Claims22
An engineered cell comprising:
- (i) the expression of at least one of the endogenous gene selected from the group consisting of:
- Fas, TNFR1, DR3, DR4, DR5, TGFBR1, TGFBR2 is down-regulated;
- and
- (ii) an exogenous immunosuppressive molecule is expressed, wherein the immunosuppressive molecule comprises one or more immunosuppressive protein-binding domains, a transmembrane domain and a co-stimulatory domain, and does not comprise a primary signaling domain, wherein the immunosuppressive protein-binding domain binds to an immunosuppressive protein selected from the group consisting of:
- PD1, NKG2A, FasL and CTLA4.
2 more elements
(canceled)
(canceled)
Dependencies are inferred from the claim text.